Personalis (NASDAQ:PSNL) CFO Aaron Tachibana Sells 38,799 Shares

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 38,799 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $11.58, for a total transaction of $449,292.42. Following the completion of the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at approximately $2,302,486.14. This represents a 16.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Performance

NASDAQ:PSNL opened at $11.40 on Friday. Personalis, Inc. has a one year low of $3.84 and a one year high of $11.85. The firm has a market cap of $1.19 billion, a P/E ratio of -11.18 and a beta of 1.96. The firm has a 50-day simple moving average of $6.86 and a 200-day simple moving average of $8.10.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.49 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. On average, research analysts predict that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PSNL. Caitong International Asset Management Co. Ltd increased its stake in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares in the last quarter. Legal & General Group Plc acquired a new position in Personalis during the 2nd quarter valued at approximately $30,000. International Assets Investment Management LLC acquired a new position in Personalis during the 4th quarter valued at approximately $31,000. BNP Paribas Financial Markets increased its stake in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares in the last quarter. Finally, Focus Partners Wealth acquired a new position in Personalis during the 1st quarter valued at approximately $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. BTIG Research cut their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Needham & Company LLC increased their price objective on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Morgan Stanley decreased their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.